Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: A possible protective effect against disease progression

Blood

Volumn 107, Issue 12, 2006, Pages 4825-4833

  Pastori, Claudia ^b   Weiser, Barbara ^b   Barassi, Claudia ^b   Uberti Foppa, Caterina ^b   Ghezzi, Silvia ^b   Longhi, Renato ^b   Calori, Giliola ^b   Burger, Harold ^b   Kemal, Kimdar ^b   Poli, Guido ^b   Lazzarin, Adriano ^b   Lopalco, Lucia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTIBODY; CLATHRIN; CYTOKINE ANTIBODY; EPITOPE; IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FOLLOW UP; GENE MUTATION; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INTERNALIZATION; MAJOR CLINICAL STUDY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR DOWN REGULATION; T LYMPHOCYTE; VIROLOGY; VIRUS STRAIN;

EID: 33745077706     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2463     Document Type: Article

References (52)

1. Rodes B, Toro C, Paxinos E, et al. Differences in disease progression in a cohort of long-term nonprogressors after more than 16 years of HIV-1 infection. AIDS. 2004;18:1109-1116.
2. Lopalco L. Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? Curr HIV Res. 2004;2:79-92.
3. Paroli M, Propato A, Accapezzato D, Francavilla V, Schiaffella E, Barnaba V. The immunology of HIV-infected long-term non-progressors - a current view. Immunol Lett. 2001;79:127-129.
4. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis. 1996;173:60-67.
5. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med. 1995;332:201-208.
6. Martinez V, Costagliola D, Bonduelle O, et al. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis. 2005;191:2053-2063.
7. Zhang YJ, Fracasso C, Fiore JR, et al. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis. 1997;176:1180-1187.
8. Cecilia D, Kleeberger C, Munoz A, Giorgi JV, Zolla-Pazner S. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis. 1999;179:1365-1374.
9. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis. 1997;176:924-932.
10. Stewart-Jones GBE, Gillespie G, Overton IM, et al. Structures of three HIV-1 HLA-B*5703.peptide complexes and identification of related HLAs potentially associated with long-term nonprogression. J Immunol. 2005;175:2459-2468.
11. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9:861-866.
12. Catucci M, Venturi G, Romano L, Valensin PE, Zazzi M. Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. J Med Virol. 2000;60:294-299.
13. Brambilla A, Turchetto L, Gatti A, et al. Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Virology. 1999;259:349-368.
14. Hassaine G, Agostini I, Candotti D, et al. Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology. 2000;276:169-180.
15. Lum JJ, Cohen OJ, Nie Z, et al. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J Clin Invest. 2003;111:1547-1554.
16. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661-666.
17. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1 [letter]. Nature. 1998;391:240.
18. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest. 1994;94:2060-2067.
19. Lopalco L, Barassi C, Pastori C, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro. J Immunol. 2000;164:3426-3433.
20. Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood. 2004;104:2205-2206.
21. Propato A, Schiaffella E, Vicenzi E, et al. Spreading of HIV-specific CD8 T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol. 2001;62:561-576.
22. Philpott S, Weiser B, Anastos K, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest. 2001;107:431-438.
23. Liu R, Paxton W, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:1-11.
24. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med. 1998;4:350-353.
25. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science. 1998;279:389-393.
26. Brambilla A, Villa C, Rizzardi G, et al. Shorter survival of SDF1-3′A/3′A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis. 2000;182:311-315.
27. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996;384:184-187.
28. Grassi F, Meneveri R, Gullberg M, et al. Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains. J Exp Med. 1991;174:53-62.
29. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35:161-214.
30. King DS, Fields CG, Fields GB. A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis. Int J Pept Protein Res. 1990;36:255-266.
31. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185:1681-1691.
32. Mueller A, Kelly E, Strange PG. Pathways for internalization and recycling of the chemokine receptor CCR5. Blood. 2002;99:785-791.
33. Clerici M, Barassi C, Devito C, et al. Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the alpha-helix of gp41. AIDS. 2002;16:1731-1741.
34. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol. 2003;77:5678-5684.
35. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995;206:935-944.
36. Lopalco L, Pastori C, Cosma A, et al. Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses. 2000;16:109-115.
37. Mack M, Luckow B, Nelson PJ, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med. 1998;187:1215-1224.
38. Solari R, Offord RE, Remy S, et al. Receptor-mediated endocytosis of CC-chemokines. J Biol Chem. 1997;272:9617-9620.
39. Signoret N, de Jong J, Goudsmit J, Sattentau QJ. Mutations within the CD4-CDR-3-like loop allow replication in an immortalized T cell line of HIV type 1 viruses chimeric for envelope glycoproteins containing non-syncytium-inducing V3 loops. AIDS Res Hum Retroviruses. 1997;13:121-123.
40. Lopalco L, Magnani Z, Confetti C, et al. Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. AIDS Res Hum Retroviruses. 1999;15:1079-1085.
41. Parren PW, Moore JP, Burton DR, Sattentau QJ. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. Aids. 1999;13(Suppl A):S137-162.
42. Ditzel HJ, Rosenkilde MM, Garred P, et al. The CCR5 receptor acts as an alloantigen in CCR5 Delta32 homozygous individuals: identification of chemokine and HIV-1-blocking human antibodies. Proc Natl Acad Sci U S A. 1998;95:5241-5245.
43. Locati M, Murphy PM. Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. Annu Rev Med. 1999;50:425-440.
44. Venkatesan S, Rose JJ, Lodge R, Murphy PM, Foley JF. Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell. 2003;14:3305-3324.
45. Signoret N, Hewlett L, Wavre S, Pelchen-Matthews A, Oppermann M, Marsh M. Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Mol Biol Cell. 2005;16:902-917.
46. Mack M, Luckow B, Nelson PJ, et al. Aminoxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med. 1998;187:1215-1224.
47. Blanpain C, Vanderwinden JM, Cihak J, et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell. 2002;13:723-737.
48. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses. 2005;21:171-189.
49. Brandt SM, Mariani R, Holland AU, Hope TJ, Landau NR. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J Biol Chem. 2002;277:17291-17299.
50. Barassi C, Soprana E, Pastori C, et al. Induction of murine mucosal CCR5-reactive antibodies as anti-HIV strategy. J Virology. 2005;79:6848-6858.
51. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235-270.
52. Wolinsky SM, Veazey RS, Kunstman KJ, et al. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology. 2004;328:19-29.